Doximity, Inc. (DOCS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Last but not least, we're pleased to announce the acquisition of Pathway, a six-person, -year-old Montreal startup specializing in AI clinical reference. Trained at McGill, Johns Hopkins, and Harvard, physicians make up half the team at Pathway. From a postdoc program at the prestigious Miele AI Institute, they founded Pathway five years before CHET GPT even existed. To help answer the ICU bedside questions they faced every day. Together, they painstakingly built one of the best and largest medical AI datasets around, spanning nearly every guideline, drug, journal, and landmark trial. They call this their corpus. And what makes it powerful is its cross-linked structure that lets AI quickly get accurate answers for doctors. It's much more than an LLM. It understands complex drug interactions and scores the strength of medical evidence, such as weighing a validated clinical trial more than a case study. The net result is industry-leading accuracy and speed. This May, Pathway's AI model scored a record high, 96%, on the U.S. medical licensing exam, outperforming their competitors. With almost no marketing budget, Pathway has grown to hundreds of thousands of registered users worldwide, with thousands paying $300 per year for their premium version. Above all, this AI native aqua-hire has been a great culture and mission fit for us. Over the past month, we've spent many a late night working with the Pathway team at our San Francisco offices. They're smart, honest, and hardworking, and we just couldn't like them more. We've already learned a lot from John, Louis, Chris, Kudder, Hove, and Peter. And yes, I'm calling them out here not just to thank them, but also to help them get visas to move here. The fruits of our collaboration are already on display. In record time, our ...